CD274 and adenocarcinoma: The evidence from the literature data is sufficient to conclude the following: (1) the addition of immunotherapy to radiotherapy or immunotherapy alone improves 1- and 3-year overall survival; (2) progression-free survival is significantly influenced by ICI-RT association; and (3) gain in overall survival seems be retained in adenocarcinoma and PD-L1 negative patients.